U

University Eye Specialists | Clinical Research Department

Research site

(Unclaimed)

Location

622 Smithview Drive, Maryville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Timolol Maleate

Latanoprost

Netarsudil

AR-15512

H-1337

STN1013600

Bimatoprost

AR-17043

DE-126

PG043

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 13 total trials

Status recently updated

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Pseudophakic Eyes (EVOLVE)

A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment in Pse...

Not yet enrolling

Enrolling

Primary Open Angle Glaucoma

Drug: Latanoprost plus adjunctive glaucoma medication

Device: OMNI Surgical System

Next Generation Rocklatan

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects...

Not yet enrolling

Open Angle Glaucoma

Ocular Hypertension

Drug: AR-17043 Ophthalmic Solution

Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma (VENICE)

A study of the Streamline Surgical System versus competitor

Enrolling

Open Angle Glaucoma

Device: Streamline Surgical System

Device: iStent Inject W

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q...

Active, not recruiting

Glaucoma Open-Angle Primary

Ocular Hypertension

Drug: Timolol 0.5%

Drug: H-1337 Placebo